PacBio Partners with UW Medicine to Study Sudden Unexplained Death in Childhood
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy PACB?
PacBio announced that a UW Medicine and Seattle Children's research effort led by Danny Miller, MD, PhD, and Alexandra Keefe, MD, PhD, will employ PacBio HiFi whole-genome sequencing as the first-line approach to investigate Sudden Unexplained Death in Childhood. "Backed by the SUDC Foundation and with in-kind support from PacBio, the project will sequence each child and their parents, prioritizing long-read HiFi data for comprehensive variant detection. Additionally, the University of Washington team will join the HiFi Solves Global Consortium, which brings together institutions around the world to study the value HiFi-based human genome sequencing may have in clinical research applications and to further our understanding of genetic diseases," PacBio said.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PACB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PACB
Wall Street analysts forecast PACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB is 2.40 USD with a low forecast of 2.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.715
Low
2.00
Averages
2.40
High
3.00
Current: 1.715
Low
2.00
Averages
2.40
High
3.00
About PACB
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PacBio Completes Sale of Short-Read DNA Technology Assets
- Asset Sale Completion: PacBio completed the sale of short-read DNA sequencing technology assets to Illumina for $48.1 million in net cash proceeds, aimed at strengthening its balance sheet and refocusing on long-read sequencing development.
- Strategic Shift: In response to challenging macroeconomic conditions, PacBio paused the development of its high-throughput short-read sequencing platform, reallocating resources to innovations in the long-read sequencing market, which is expected to enhance its market share.
- Accelerated Technology Development: The transaction enables PacBio to expedite the development of SPRQ-Nx chemistry, which will be launched globally at a competitive pricing structure, providing a more comprehensive view of the genome and further solidifying its leadership in genomic sequencing.
- Future Growth Potential: The CEO of PacBio stated that this transaction not only strengthens the company's balance sheet but also lays the groundwork for the next phase of growth, expected to drive the adoption of its differentiated long-read sequencing platform and enhance market competitiveness.
See More
Pacific Biosciences Announces Q4 and Full Year 2025 Financial Results Date
- Earnings Release Date: Pacific Biosciences will report its Q4 and full-year 2025 financial results on February 12, 2026, at 5:00 PM ET, demonstrating the company's commitment to transparency and investor communication.
- Revenue Growth: Preliminary fourth-quarter revenue is expected to reach approximately $44.6 million, reflecting a 14% year-over-year increase, while full-year revenue is projected at $160 million, a 4% rise from the previous year, driven primarily by strong sales of the Vega sequencing platform.
- System Placement Trends: The deployment count for the Vega system surged to 42 units in Q4 2025 from just 7 units a year earlier, while the Revio system placements slightly declined to 21 units, indicating a market preference shift towards the Vega platform.
- Stock Performance: Over the past year, PACB's stock traded between $1.84 and $2.12, closing at $2.57 with a 1.98% increase, reflecting market confidence in the company's growth potential.
See More
Pacific Biosciences (PACB) Reports 14% Q4 Revenue Growth for 2025
- Revenue Growth: Pacific Biosciences anticipates approximately $44.6 million in Q4 2025 revenue, up 14% from $39.2 million in the prior year, driven by strong sales of its Vega sequencing platform, indicating robust performance.
- Instrument and Consumables Revenue: Q4 2025 instrument revenue is expected to rise to $17.3 million from $15.3 million, while consumables revenue jumps from $18.8 million to $21.6 million, reflecting sustained market demand and operational efficiency.
- System Deployment Trends: The placement count for the Vega system surged to 42 units in Q4 2025 from 7 units year-over-year, while the Revio system placements declined from 23 to 21 units, highlighting a shift in market preference towards Vega amid challenges for Revio.
- Future Outlook: CEO Christian Henry noted that the SPRQ-Nx technology's cost reductions and enhanced multiomic capabilities are expected to catalyze growth in 2026 and beyond, demonstrating the company's confidence in future market opportunities.
See More
PacBio Unveils CiFi Technology for Chromosome-Scale Assemblies in Single Sequencing Run
- Technological Innovation: PacBio's newly launched CiFi method integrates 3C with HiFi long-read sequencing, enabling chromosome-scale assemblies in a single sequencing run, significantly enhancing efficiency and accuracy in genomic research.
- Reduced Sample Requirements: This technology allows for the generation of reference-quality assemblies with limited sample input, thereby lowering the costs and complexities associated with genome projects by requiring fewer cells and libraries.
- Multi-Contact Resolution Capability: CiFi overcomes the limitations of traditional Hi-C methods by producing long HiFi reads that capture multiple chromatin interactions, which increases contact density and improves data quality.
- Broad Application Prospects: The successful application of this technology in assembling the genomes of prairie and meadow voles demonstrates its potential value in biodiversity studies and functional genomics, indicating a wide range of future applications in the field of genomics.
See More
ARK Invest Increases Holdings in Gene Editing Firms, PACB Stock Rises
- Investment Strategy Shift: ARK Invest has aggressively trimmed legacy winners like Tesla to fund a multi-million dollar accumulation of gene-editing pioneers, indicating strong confidence in the genomic revolution.
- Increased Holdings in Gene Editing Firms: By late December 2025, ARK increased its stake in CRISPR Therapeutics to over 5% and Beam Therapeutics to 3.41%, enhancing its market position in the genomic revolution.
- AI and Biotechnology Integration: Cathie Wood emphasized the transformative potential of AI in healthcare, asserting that AI accelerates all aspects of genomics, thereby improving drug development and disease diagnosis efficiency.
- Fund Diversification: ARK has also established the Ark Genomic Revolution Fund, dedicated to investing in companies relevant to the genomic revolution across healthcare and information technology sectors, further expanding its investment portfolio.
See More
Pacific Biosciences Raises Price Target to $2, Outlook Positive
- Analyst Optimism: Barclays analyst Luke Sergott raised the price target for Pacific Biosciences (PACB) from $1.50 to $2 while maintaining an Equal Weight rating, reflecting a positive outlook for the life sciences and diagnostics tools sector.
- Revenue Forecast Adjustment: Despite last quarter's revenue of $38.4 million falling slightly short of expectations due to lower-than-anticipated Vega sales in Europe, the company anticipates a sequential revenue growth of about 10% in Q4, indicating a rebound in market demand.
- Sales Projections Downgrade: Pacific Biosciences has lowered its full-year sales forecast for 2025 to a range of $155 million to $160 million, reflecting a cautious approach to market conditions while indicating strategic adjustments to address challenges.
- Innovation Potential: As a developer of innovative DNA sequencing technology, PACB plays a crucial role in aiding researchers to understand complex genomes, and despite facing competition, its unique technology and market demand provide a foundation for future growth.
See More
PacBio Completes Sale of Short-Read DNA Technology Assets
- Asset Sale Completion: PacBio completed the sale of short-read DNA sequencing technology assets to Illumina for $48.1 million in net cash proceeds, aimed at strengthening its balance sheet and refocusing on long-read sequencing development.
- Strategic Shift: In response to challenging macroeconomic conditions, PacBio paused the development of its high-throughput short-read sequencing platform, reallocating resources to innovations in the long-read sequencing market, which is expected to enhance its market share.
- Accelerated Technology Development: The transaction enables PacBio to expedite the development of SPRQ-Nx chemistry, which will be launched globally at a competitive pricing structure, providing a more comprehensive view of the genome and further solidifying its leadership in genomic sequencing.
- Future Growth Potential: The CEO of PacBio stated that this transaction not only strengthens the company's balance sheet but also lays the groundwork for the next phase of growth, expected to drive the adoption of its differentiated long-read sequencing platform and enhance market competitiveness.
See More
Pacific Biosciences Announces Q4 and Full Year 2025 Financial Results Date
- Earnings Release Date: Pacific Biosciences will report its Q4 and full-year 2025 financial results on February 12, 2026, at 5:00 PM ET, demonstrating the company's commitment to transparency and investor communication.
- Revenue Growth: Preliminary fourth-quarter revenue is expected to reach approximately $44.6 million, reflecting a 14% year-over-year increase, while full-year revenue is projected at $160 million, a 4% rise from the previous year, driven primarily by strong sales of the Vega sequencing platform.
- System Placement Trends: The deployment count for the Vega system surged to 42 units in Q4 2025 from just 7 units a year earlier, while the Revio system placements slightly declined to 21 units, indicating a market preference shift towards the Vega platform.
- Stock Performance: Over the past year, PACB's stock traded between $1.84 and $2.12, closing at $2.57 with a 1.98% increase, reflecting market confidence in the company's growth potential.
See More
Pacific Biosciences (PACB) Reports 14% Q4 Revenue Growth for 2025
- Revenue Growth: Pacific Biosciences anticipates approximately $44.6 million in Q4 2025 revenue, up 14% from $39.2 million in the prior year, driven by strong sales of its Vega sequencing platform, indicating robust performance.
- Instrument and Consumables Revenue: Q4 2025 instrument revenue is expected to rise to $17.3 million from $15.3 million, while consumables revenue jumps from $18.8 million to $21.6 million, reflecting sustained market demand and operational efficiency.
- System Deployment Trends: The placement count for the Vega system surged to 42 units in Q4 2025 from 7 units year-over-year, while the Revio system placements declined from 23 to 21 units, highlighting a shift in market preference towards Vega amid challenges for Revio.
- Future Outlook: CEO Christian Henry noted that the SPRQ-Nx technology's cost reductions and enhanced multiomic capabilities are expected to catalyze growth in 2026 and beyond, demonstrating the company's confidence in future market opportunities.
See More
PacBio Unveils CiFi Technology for Chromosome-Scale Assemblies in Single Sequencing Run
- Technological Innovation: PacBio's newly launched CiFi method integrates 3C with HiFi long-read sequencing, enabling chromosome-scale assemblies in a single sequencing run, significantly enhancing efficiency and accuracy in genomic research.
- Reduced Sample Requirements: This technology allows for the generation of reference-quality assemblies with limited sample input, thereby lowering the costs and complexities associated with genome projects by requiring fewer cells and libraries.
- Multi-Contact Resolution Capability: CiFi overcomes the limitations of traditional Hi-C methods by producing long HiFi reads that capture multiple chromatin interactions, which increases contact density and improves data quality.
- Broad Application Prospects: The successful application of this technology in assembling the genomes of prairie and meadow voles demonstrates its potential value in biodiversity studies and functional genomics, indicating a wide range of future applications in the field of genomics.
See More
ARK Invest Increases Holdings in Gene Editing Firms, PACB Stock Rises
- Investment Strategy Shift: ARK Invest has aggressively trimmed legacy winners like Tesla to fund a multi-million dollar accumulation of gene-editing pioneers, indicating strong confidence in the genomic revolution.
- Increased Holdings in Gene Editing Firms: By late December 2025, ARK increased its stake in CRISPR Therapeutics to over 5% and Beam Therapeutics to 3.41%, enhancing its market position in the genomic revolution.
- AI and Biotechnology Integration: Cathie Wood emphasized the transformative potential of AI in healthcare, asserting that AI accelerates all aspects of genomics, thereby improving drug development and disease diagnosis efficiency.
- Fund Diversification: ARK has also established the Ark Genomic Revolution Fund, dedicated to investing in companies relevant to the genomic revolution across healthcare and information technology sectors, further expanding its investment portfolio.
See More
Pacific Biosciences Raises Price Target to $2, Outlook Positive
- Analyst Optimism: Barclays analyst Luke Sergott raised the price target for Pacific Biosciences (PACB) from $1.50 to $2 while maintaining an Equal Weight rating, reflecting a positive outlook for the life sciences and diagnostics tools sector.
- Revenue Forecast Adjustment: Despite last quarter's revenue of $38.4 million falling slightly short of expectations due to lower-than-anticipated Vega sales in Europe, the company anticipates a sequential revenue growth of about 10% in Q4, indicating a rebound in market demand.
- Sales Projections Downgrade: Pacific Biosciences has lowered its full-year sales forecast for 2025 to a range of $155 million to $160 million, reflecting a cautious approach to market conditions while indicating strategic adjustments to address challenges.
- Innovation Potential: As a developer of innovative DNA sequencing technology, PACB plays a crucial role in aiding researchers to understand complex genomes, and despite facing competition, its unique technology and market demand provide a foundation for future growth.
See More
